-
CycleTrack and SDN are teaming up to make medical school admissions more transparent and accessible! Read the announcement to learn how we’re supporting the future of CycleTrack’s free application-tracking tools .
Get help with your application
Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.
Advertisement - Members don't see this ad
I wonder who's going to be first in line to pay a premium for a drug that will (probably) expire (multiple times) before it's used, and isn't any more effective than the stuff they've already got?
I don't think their goal is for it to be popular in MH...
http://www.eagleus.com/products/late-stage-drug-pipeline/ryanodex-ehs
It's much easier to get drugs approved via the orphan drug route. Once its approved, doctors can use it off-label. If they can convince some docs to use it off-label or show efficacy with an animal model...it's a much more valuable drug to them as it treats a condition that is way more prevalent that has only symptomatic management at this point.
http://www.eagleus.com/products/late-stage-drug-pipeline/ryanodex-ehs
It's much easier to get drugs approved via the orphan drug route. Once its approved, doctors can use it off-label. If they can convince some docs to use it off-label or show efficacy with an animal model...it's a much more valuable drug to them as it treats a condition that is way more prevalent that has only symptomatic management at this point.
Last edited:
